STOCK TITAN

Regenxbio - RGNX STOCK NEWS

Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.

Regenxbio Inc (RGNX) is a clinical-stage biotechnology leader advancing novel AAV gene therapies through its proprietary NAV® technology platform. This page provides investors and stakeholders with centralized access to the company’s latest press releases, clinical trial updates, and strategic developments.

Track critical updates across Regenxbio’s pipeline, including progress on RGX-202 for Duchenne muscular dystrophy, RGX-121 for Hunter syndrome, and ABBV-RGX-314 for retinal diseases. Stay informed about regulatory milestones, manufacturing advancements, and partnership announcements with entities like AbbVie.

All content is sourced directly from Regenxbio’s official communications, ensuring accuracy and timeliness. Bookmark this page for streamlined access to essential updates on one-time gene therapies targeting rare genetic disorders.

Rhea-AI Summary

REGENXBIO reported its first quarter 2024 financial results and recent operational highlights, showcasing progress towards BLA filing in 2024 and pivotal trial initiations for Duchenne and diabetic retinopathy. The company announced positive interim efficacy and safety data, cash reserves of $381 million, and planned meetings with the FDA. Program highlights include advancements in neuromuscular and retinal diseases. Financially, revenues decreased to $15.6 million, with increased cash position but higher R&D and G&A expenses leading to a net loss of $63.3 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.94%
Tags
-
Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results and operational highlights. Listeners can register for the webcast to participate in the Q&A session. A replay will be available on the investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.22%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.5%
Tags
conferences clinical trial

FAQ

What is the current stock price of Regenxbio (RGNX)?

The current stock price of Regenxbio (RGNX) is $9.13 as of April 28, 2025.

What is the market cap of Regenxbio (RGNX)?

The market cap of Regenxbio (RGNX) is approximately 452.2M.
Regenxbio

Nasdaq:RGNX

RGNX Rankings

RGNX Stock Data

452.22M
46.30M
7.31%
87.5%
12.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
ROCKVILLE